Table 1.
Summary of currently conducted studies on COVID-19 drugs according to: drugvirus.info (Andersen et al., 2020; Drugvirus.info, 2021), clinicaltrials.gov (US National Library of Medicine, 2020) (updated on – 27th of July 2021).
| Therapeutic agent | Number of phase III-IV clinical trials |
|---|---|
| Amantadine | 3 |
| ASA | 10 |
| Azithromycin | 41 |
| Bamlanivimab - etesevimab | 3 |
| Baricitinib | 13 |
| Camostat mesylate | 6 |
| Casirivimab/ imdevimab | 3 |
| Chloroquine | 13 |
| Dexamethasone | 29 |
| Favipiravir | 21 |
| HCQ | 117 |
| Imatinib | 2 |
| IFN-β-1a | 11 |
| Isotretinoin | 3 |
| Ivermectin | 37 |
| Lopinavir/ritonavir | 20 |
| Mefloquine | 2 |
| Nafamostat mesylate | 5 |
| Niclosamide | 4 |
| Nitazoxanide | 18 |
| Oseltamivir | 7 |
| Remdesivir | 46 |
| Ribavirin | 3 |
| Sofosbuvir | 8 |
| Sotrovimab | 2 |
| Tocilizumab | 23 |
| Umifenovir | 4 |
Legend: ASA – acetylsalicylic acid, aspirin; HCQ – hydroxychloroquine; IFN-interferon.